1. Academic Validation
  2. Hexokinase 2 nonmetabolic function-mediated phosphorylation of IκBα enhances pancreatic ductal adenocarcinoma progression

Hexokinase 2 nonmetabolic function-mediated phosphorylation of IκBα enhances pancreatic ductal adenocarcinoma progression

  • Cancer Sci. 2024 May 27. doi: 10.1111/cas.16204.
Yingying Tong 1 Xin Liu 1 Lihui Wu 2 Yaoxian Xiang 1 Jing Wang 1 Yurong Cheng 1 Chan Zhang 1 Baojuan Han 1 Li Wang 1 Dong Yan 1
Affiliations

Affiliations

  • 1 Cancer Center, Beijing Luhe Hospital, Capital Medical University, Beijing, China.
  • 2 Zhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Abstract

Aberrant signaling in tumor cells induces nonmetabolic functions of some metabolic Enzymes in many cellular activities. As a key glycolytic Enzyme, the nonmetabolic function of Hexokinase 2 (HK2) plays a role in tumor immune evasion. However, whether HK2, dependent of its nonmetabolic activity, plays a role in human pancreatic ductal adenocarcinoma (PDAC) tumorigenesis remains unclear. Here, we demonstrated that HK2 acts as a protein kinase and phosphorylates IκBα at T291 in PDAC cells, activating NF-κB, which enters the nucleus and promotes the expression of downstream targets under hypoxia. HK2 nonmetabolic activity-promoted activation of NF-κB promotes the proliferation, migration, and invasion of PDAC cells. These findings provide new insights into the multifaceted roles of HK2 in tumor development and underscore the potential of targeting HK2 protein kinase activity for PDAC treatment.

Keywords

HK2; IκBα; nonmetabolic activity; pancreatic ductal adenocarcinoma; tumor progression.

Figures
Products